- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07870330
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Moderna WeCare Team
- Telefonnummer: +1-866-663-3762
- E-mail: WeCareClinicalTrials@modernatx.com
Studiesteder
-
-
California
-
Modesto, California, Forenede Stater, 95355
- Rekruttering
- Paradigm Clinical Research Centers, LLC
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rekruttering
- Paradigm Clinical Research Centers, LLC
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55402
- Rekruttering
- Clinical Research Institute, Inc
-
-
Ohio
-
South Euclid, Ohio, Forenede Stater, 44121
- Rekruttering
- Senders Pediatrics
-
-
Texas
-
Houston, Texas, Forenede Stater, 77055
- Rekruttering
- West Houston Clinical Research Service
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23226
- Rekruttering
- Clinical Research Partners, LLC.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 9 to <18 years of age inclusive, at the time of signing the informed consent/assent.
- In the Investigator's opinion, the participants/participant's parent(s)/legally authorized representative (LAR(s)) demonstrate adequate understanding of the study requirements and are willing and physically able to comply with protocol mandated follow-up, including all procedures.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.
Exclusion Criteria:
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic; influenza vaccine; or components of influenza vaccine, including egg protein.
- Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the window specified for Screening.
- History of a diagnosis or condition not specifically listed as exclusionary that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.
- Any prior systemic immunosuppressants, immunomodulators (for example, methotrexate, cyclosporine), or long-acting biological therapies that may affect immune responses (for example, dupilumab, omalizumab). Short courses (<7 days) of oral corticosteroids are allowed if completed at least 3 months prior to Day 1. Inhaled, nasal, topical steroids, and subcutaneous injected allergy immunotherapy (allergy shots) are allowed.
- Received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.
- Received any nonstudy vaccine authorized or approved by local health agency within 14 days (28 days for live vaccines and mRNA vaccines) prior to Day 1 (inclusive) or plans to receive any nonstudy vaccine within 28 days post study vaccine administration.
- Donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study vaccine administration.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: mRNA-1010 Low Dose
Participants will receive a single low dose of mRNA-1010 by intramuscular (IM) injection on Day 1. |
Suspension for injection
Andre navne:
|
|
Eksperimentel: mRNA-1010 Full Dose
Participants will receive a single full dose of mRNA-1010 by intramuscular (IM) injection on Day 1. |
Suspension for injection
Andre navne:
|
|
Aktiv komparator: Fluarix Trivalent
Participants will receive a single dose of Fluarix Trivalent by IM injection on Day 1. |
Suspension for injection
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Geometrisk middeltiter (GMT) af anti-hæmagglutinin (HA) antistoffer på dag 29, målt ved hæmagglutinationshæmningsassay (HAI)
Tidsramme: Dag 29
|
Dag 29
|
|
|
Procentdel af deltagere med HAI-titer ≥ 1:40 på dag 29
Tidsramme: Dag 29
|
Dag 29
|
|
|
Antal deltagere med anmodede lokale og systemiske reaktogenicitetsbivirkninger (AR'er)
Tidsramme: Op til dag 7 (7 dage efter vaccination)
|
Op til dag 7 (7 dage efter vaccination)
|
|
|
Antal deltagere med uopfordrede bivirkninger (AE'er)
Tidsramme: Op til dag 28 (28 dage efter vaccination)
|
Op til dag 28 (28 dage efter vaccination)
|
|
|
Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)
Tidsramme: Day 1 through Day 365
|
Day 1 through Day 365
|
|
|
Number of Participants with Medically Attended AEs (MAAEs)
Tidsramme: Day 1 through Day 181
|
Day 1 through Day 181
|
|
|
Percentage of Participants Reaching Seroconversion, as Measured by HAI Assay
Tidsramme: Day 29
|
Seroconversion is defined as either a pre-vaccination HAI titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. |
Day 29
|
|
Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI Assays
Tidsramme: Day 29
|
Day 29
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- mRNA-1010-P102
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .